Nanobiotix

Equities

NANO

FR0011341205

Biotechnology & Medical Research

Market Closed - Euronext Paris Other stock markets 16:35:18 10/09/2024 BST			After market 18:35:02
4.576 ^EUR	+2.60%		4.572	-0.09%

09-05	Nanobiotix: two appointments to the Supervisory Board	CF
08-28	Guggenheim Initiates Nanobiotix at Buy With $12 Price Target	MT

Nanobiotix: two appointments to the Supervisory Board

September 05, 2024 at 06:28 am

Nanobiotix announces the appointments of Margaret A Liu and Anat Naschitz as censors to its Supervisory Board, subject to ratification by its shareholders at the next Annual General Meeting.

A global expert in vaccines, gene therapy and cancer immunotherapy, Margaret A Liu is Chief Executive Officer of PAX Therapeutics and a member of several boards, including that of Ipsen.

Anat Naschitz is a seasoned life sciences investor and entrepreneur, and co-founder of OrbiMed Israel. She is CEO of 9xchange, a drug discovery software platform using AI and machine learning.

Copyright (c) 2024 CercleFinance.com. All rights reserved.

Go to the original article.
Legal disclaimer

Stocks mentioned in the article

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	IPSEN	106.80 EUR	-2.91%	-2.02%	10.03B
	NANOBIOTIX	4.576 EUR	+2.60%	-2.68%	233M

Latest news about Nanobiotix

Nanobiotix: two appointments to the Supervisory Board	09-05	CF
Guggenheim Initiates Nanobiotix at Buy With $12 Price Target	08-28	MT
Guggenheim Initiates Nanobiotix at Buy	08-28	MT
Nanobiotix: The Goldman Sachs Group crosses the 5% threshold	07-02	CF
Stifel Initiates Nanobiotix with Buy Rating	06-25	MT
Nanobiotix: well oriented on broker's comments	06-25	CF
NANOBIOTIX : Stifel initiates buy coverage	06-25	CF
Transcript : Nanobiotix S.A. - Special Call	06-18
Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated with RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 Therapy	06-03	CI
Transcript : Nanobiotix S.A. - Special Call	06-02
Nanobiotix S.A. Announces Presentation of New Data from Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology	05-28	CI
Transcript : Nanobiotix S.A., Q1 2024 Earnings Call, May 22, 2024	05-22
Nanobiotix: strategy update, share price declines	05-22	CF
Nanobiotix to Transfer Phase 3 Head and Neck Cancer Study Sponsorship	05-21	MT
Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth	05-21	CI
Nanobiotix to Proceed to Phase 2 Trial of Lung Cancer Treatment	05-14	MT
Nanobiotix Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating Nbtxr3 for Patients with Stage Three Lung Cancer	05-14	CI
Transcript : Nanobiotix S.A., Q4 2023 Earnings Call, Apr 25, 2024	04-25
Nanobiotix S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	04-24	CI
Nanobiotix S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	04-24	CI
Nanobiotix completes escalation portion of 2020-0123 study	04-03	CF
Nanobiotix Completes Dose Escalation Segment of Phase 1 Study Targeting Non-Small Cell Lung Cancer	04-02	MT
Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommends Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-Irradiation	04-02	CI
Nanobiotix Gets $20 Million Milestone Payment in Phase 3 Trial for Potential Head, Neck Cancer Drug	01-30	MT
Nanobiotix: targets achieved for NANORAY-312	01-30	CF

Chart Nanobiotix

Duration

Period

More charts

Company Profile

Nanobiotix is a pioneer and leader in nanomedicine that has developed a revolutionary approach to the treatment of cancer. The company focuses its effort on the development of its products portfolio entirely patented, NanoXray, innovation based on the physical mode of action of nanoparticles that, under the action of radiation, allow maximizing the absorption of X-rays inside the cancer cells without increasing the dose received by the surrounding healthy tissue. NanoXray products are compatible with standard radiotherapy treatments and are intended to potentially treat a wide variety of cancers via multiple routes of administration. The company's resources are primarily devoted to the development of its lead product candidate: NBTXR3, which is the product of its proprietary oncology platform and has already achieved market authorization in Europe for the treatment of patients with soft tissue sarcoma under the brand name Hensify®.

Employees

102

Sector

Biotechnology & Medical Research

Calendar

11/09/2024 - H.C. Wainwright Global Investment Conference - Fireside Chat

More about the company